GleamWall
中文EN

GLUC Glucose Health, Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1420108 · Fiscal year ends 12/31

Financial factors as of 2017-09-30 (2017Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-70.6%
TTM net income YoY73.8%
TTM EPS YoY—
Revenue 3-yr CAGR237.6%
Net income 3-yr CAGR—

Margins

Gross margin65.4%
Operating margin-36.8%
Net margin-96.5%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-241.9%
ROIC (approx.)—
Asset turnover2.51x

Leverage & solvency

Liabilities / assets1,717.4%
Debt / equity—
Current ratio0.06x
Interest coverage-0.29x

Cash quality & payout

Operating cash flow / net income0.20x
Accruals ratio-192.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20162016-12-31FY20152015-12-31
Income statement
Revenue$313,229$4,272
Cost of revenue$294,062$3,875
Gross profit$19,167$397
R&D expense—$48
SG&A expense$51,838$114,820
Operating income-$86,647-$156,173
Interest expense$323,796$120,028
Pretax income-$410,443-$266,064
Net income-$410,443-$266,064
EPS (basic)-0.15-0.14
EPS (diluted)——
Balance sheet
Cash & equivalents$20,542$2,055
Receivables$11,724$3,150
Inventory—$8,370
Current assets$32,905$15,107
Total assets$33,145$15,407
Current liabilities$528,592$403,226
Total liabilities$528,592$403,226
Shareholders' equity-$495,447-$387,819
Shares outstanding3.31M2.45M
Cash flow statement
Operating cash flow-$39,263-$115,776
Investing cash flow$250-$250
Financing cash flow$57,500$113,210
Stock-based compensation$1,875$32,775

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.